|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction显示文摘 | Eugene Braunwald Elliott M Antman John W Beasley Robert M Califf Melvin D Cheitlin Judith S Hochman Robert H Jones Dean Kereiakes Joel Kupersmith Thomas N Levin Carl J Pepine John W Schaeffer Earl E Smith David E Steward Pierre Theroux Raymond J Gibbons J | 2000 | Journal of the American College of Cardiology2000，，3： | 4 |
| 2 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 3 | Captopril: An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure显示文摘 | Brogden Rex N Todd Peter A Sorkin Eugene M | 1988 | Drugs1988，36，5： | 1 |
| 4 | Manage- ment of tumors arising in the parapharyngeal space 显示文摘 | Ricardo L C Eugene N M Jonas T J | 1990 | Laryngoscope1990，100，6： | 1 |
| 5 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 6 | Human myoblast genome therapy显示文摘Human Myoblast Genome Therapy (HMGT) is a platform technology of cell transplantation, nuclear transfer, and tissue engineering. Unlike stem cells, myoblasts are differentiated, immature cells destined to become muscles. Myoblasts cultured from satellite cells of adult muscle biopsies survive, develop, and function to revitalize degenerative muscles upon transplantation. Injection injury activates regeneration of host myofibers that fuse with the engrafted myoblasts, sharing their nuclei in a common gene pool of the syncytium. Thus, through nuclear transfer and complementation, the normal human genome can be transferred into muscles of patients with genetic disorders to achieve phenotype repair or disease prevention. Myoblasts are safe and efficient gene transfer vehicles endogenous to muscles that constitute 50% of body weight. Results of over 280 HMGT procedures on Duchenne Muscular Dystrophy (DMD) subjects in the past 15 years demonstrated absolute safety. Myoblast-injected DMD muscles showed improved histology. Strength increase at 18 months post-operatively averaged 123%. In another application of HMGT on ischemic cardiomyopathy, the first human myoblast transfer into porcine myocardium revealed that it was safe and effective. Clinical trials on approximately 220 severe cardiomyopathy patients in 15 countries showed a <10% mortality. Most subjects received autologous cells implanted on the epicardial surface during coronory artery bypass graft, or injected on the endomyocardial surface percutaneously through guiding catheters. Significant increases in left ventricular ejection fraction, wall thickness, and wall motion have been reported, with reduction in perfusion defective areas, angina, and shortness of breath. As a new modality of treatment for disease in the skeletal muscle or myocardium, HMGT emerged as safe and effective. Large randomized multi-center trials are under way to confirm these preliminary results. The future of HMGT is bright and exciting. | Peter K Law Danlin M Law Eugene KW Sim Khawja H Haider Margarita N Vakhromeeva Ilia I Berishvili Leo A Bockeria Choong-Chin Liew | 2006 | Journal of Geriatric Cardiology2006，3，3： | 1 |
| 7 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 8 | Neurilemmoma (schwannoma) of the facial nerve presenting as a parotid mass显示文摘 | Sanijay PM Eugene N Myers M | 1993 | Otolarynogol Neck Surg1993，108，1： | 1 |
| 9 | Despeckling of medical ultrasound images using data and rate adaptive lossy compression 显示文摘 | Nikhil Gupta Swamy M N S Eugene Plotkin | 2005 | IEEE Trans on Medical Imaging2005，24，6： | 1 |
| 10 | Prerequisite for cardiac aldosterone action:mineralocorticoid receptor and Ⅱ betahydroxysteroid dehydrogenase in the human heart显示文摘 | Alfaid N Eugene E | 1995 | Circulation1995，92，2： | 1 |
| 11 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials显示文摘 | Michelle L O’Donoghue Eugene Braunwald Elliott M Antman Sabina A Murphy Eric R Bates Yoseph Rozenman Alan D Michelson Raymond W Hautvast Peter N Ver Lee Sandra L Close Lei Shen Jessica L Mega Marc S Sabatine Stephen D Wiviott | 2009 | The Lancet2009，，9694： | 1 |
| 12 | Proportion of heritable paraganglioma cases and associated clinical characteristics显示文摘 | CARRIE D M EUGENE M N JUNE P A | 2001 | The Laryngoscope2001，111，10： | 1 |
| 13 | Is anterior leaflet repair always necessary in repair of bileaflet mitral valve prolapse?显示文摘 | A.Marc Gillinov Delos M Cosgrove Sudhir Wahi William J Stewart Bruce W Lytle Nicholas G Smedira Patrick M McCarthy Per N Wierup Joseph F Sabik Eugene H Blackstone | 1999 | The Annals of Thoracic Surgery1999，，3： | 1 |
| 14 | Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart显示文摘 | Lombes M Alfaidy N Eugene E | 1995 | Circulation1995，92，2： | 1 |
| 15 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 16 | Prerequisite for aldosterone action: mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase in the human heart显示文摘 | Lombes M Alfaidy N Eugene E | 1995 | Circulation1995，92，2： | 1 |
| 17 | Color Night Vision: Opponent Processing in the Fusion of Visible and IR Imagery显示文摘 | Allen M Waxman Alan N Gove David A Fay Joseph P Racamato James E Carrick Michael C Seibert Eugene D Savoye | 1996 | Neural Networks1996，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员